Literature DB >> 33798913

LncRNA-HCG18 regulates the viability, apoptosis, migration, invasion and epithelial-mesenchymal transition of papillary thyroid cancer cells via regulating the miR-106a-5p/PPP2R2A axis.

Yue Zhu1, Jindan Zhao2, Langping Tan1, Shaojian Lin1, Miaoyun Long1, Xinzhi Peng3.   

Abstract

The incidence of papillary thyroid cancer (PTC) has experienced a rapid increase in recent years. Long non-coding RNA-homo sapiens HLA complex group (HCG) 18 plays a regulatory role in cancers, but its role in PTC remained unknown. This study determined the expressions of HCG18, microRNA (miR)-106a-5p, and protein phosphatase 2 regulatory subunit B alpha (PPP2R2A) in PTC tissues and cells by qRT-PCR. ENCORI predicted the targeting relation between HCG18 and miR-106a-5p. TargetScan v7.2 predicted the targeting relation between miR-106a-5p and PPP2R2A. Dual-luciferase reporter assay was performed to validate the two targeting relations. The viability, migration, and invasion of PTC cells were detected by Cell Counting Kit-8, wound healing assay, and Transwell assay, respectively. The expressions of matrix metalloproteinase 2 (MMP-2), MMP-9, E-cadherin, N-cadherin, and Vimentin in TPC-1 and MDA-T68 cells were assessed by qRT-PCR and Western blot. It was found that HCG18 was down-regulated in PTC. Overexpressing HCG18 suppressed viability, migration, and invasion, promoted apoptosis, and inhibited miR-106a-5p expression in PTC cells. HCG18 interacted with miR-106a-5p, the expression of which was upregulated in PTC. Upregulating miR-106a-5p expression by lentivirus infection promoted viability, migration and invasion and inhibited apoptosis of PTC cells, reversed the effect of HCG18 on the biological behaviors of PTC cells, and promoted the expressions of MMP-2, MMP-9, E-cadherin, and Vimentin and downregulated E-cadherin expression in PTC cells. PPP2R2A, a direct target of miR-106a-5p, was downregulated in PTC, and HCG18 promoted PPP2R2A expression in PTC cells by sponging miR-106a-5p. Furthermore, PPP2R2A reversed the effects of miR-106a-5p on PTC cells. In conclusion, HCG18 suppressed viability, migration, invasion and epithelial-mesenchymal transition and promoted apoptosis of PTC cells via regulating the miR-106a-5p/PPP2R2A axis.
Copyright © 2021 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  HCG18; Invasion; Migration; PPP2R2A; Papillary thyroid cancer; epithelial–mesenchymal transition; miR-106a-5p

Year:  2021        PMID: 33798913     DOI: 10.1016/j.prp.2021.153395

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

1.  LncRNA HCG18 facilitates melanoma progression by modulating miR-324-5p/CDK16 axis.

Authors:  Chengwei Zhang; Haitao Lv; Fengling Zhang; Aihua Ji
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

2.  Long non-coding RNA human leucocyte antigen complex group-18 HCG18 (HCG18) promoted cell proliferation and migration in head and neck squamous cell carcinoma through cyclin D1-WNT pathway.

Authors:  Bin Mao; Fan Wang; Jingxia Zhang; Qianqian Li; Kai Ying
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

3.  LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b.

Authors:  Fan Zhang; Bai-Hua Luo; Qi-Hui Wu; Qing-Ling Li; Ke-Da Yang
Journal:  Mol Med       Date:  2022-01-04       Impact factor: 6.354

4.  Long non-coding RNA CATIP antisense RNA 1 (lncRNA CATIP-AS1) downregulation contributes to the progression and metastasis of thyroid cancer via epithelial-mesenchymal transition (EMT) pathway.

Authors:  Fujian Qi; Ji'Ao Tang; Zhenling Cai; Gang Wang; Zhijun Wang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  Identification of an autophagy-related 12-lncRNA signature and evaluation of NFYC-AS1 as a pro-cancer factor in lung adenocarcinoma.

Authors:  Fang Tong; Lifa Xu; Sheng Xu; Mingming Zhang
Journal:  Front Genet       Date:  2022-08-11       Impact factor: 4.772

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.